oxybutynin has been researched along with Hypergonadotropic Hypogonadism in 6 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In men with hypogonadism and preexisting or a high risk of cardiovascular disease, testosterone-replacement therapy was noninferior to placebo with respect to the incidence of major adverse cardiac events." | 3.30 | Cardiovascular Safety of Testosterone-Replacement Therapy. ( Basaria, S; Bhasin, S; Boden, WE; Chan, A; Cunningham, GR; Davey, D; Dubcenco, E; Flevaris, P; Granger, CB; Huang, B; Kalahasti, V; Khan, N; Khera, M; Li, X; Lincoff, AM; Miller, MG; Mitchell, LM; Nissen, SE; Pencina, KM; Snabes, MC; Thompson, IM; Travison, TG; Wang, Q; Wolski, K; Yi, T, 2023) |
| "Male hypogonadism has been treated with exogenous testosterone since the 1930s." | 2.52 | Transdermal delivery of testosterone. ( Hadgraft, J; Lane, ME, 2015) |
| "Male hypogonadism is a condition characterized by inadequate testicular production of sex steroids and sperms; however, the term is more commonly used to identify testosterone (T) deficiency." | 2.47 | Update in testosterone therapy for men. ( Corona, G; Forti, G; Maggi, M; Rastrelli, G, 2011) |
| " They represent an improvement compared with transdermal delivery by patches because they offer more dosage flexibility, less irritation potential and a better cosmetic appearance." | 2.43 | Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery. ( Alberti, I; Carrara, DN; Grenier, A; Kraus, H, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alberti, I | 1 |
| Grenier, A | 1 |
| Kraus, H | 1 |
| Carrara, DN | 1 |
| Lincoff, AM | 1 |
| Bhasin, S | 1 |
| Flevaris, P | 1 |
| Mitchell, LM | 1 |
| Basaria, S | 1 |
| Boden, WE | 1 |
| Cunningham, GR | 1 |
| Granger, CB | 1 |
| Khera, M | 1 |
| Thompson, IM | 1 |
| Wang, Q | 1 |
| Wolski, K | 1 |
| Davey, D | 1 |
| Kalahasti, V | 1 |
| Khan, N | 1 |
| Miller, MG | 1 |
| Snabes, MC | 1 |
| Chan, A | 1 |
| Dubcenco, E | 1 |
| Li, X | 1 |
| Yi, T | 1 |
| Huang, B | 1 |
| Pencina, KM | 1 |
| Travison, TG | 1 |
| Nissen, SE | 1 |
| Hadgraft, J | 1 |
| Lane, ME | 1 |
| Corona, G | 1 |
| Rastrelli, G | 1 |
| Forti, G | 1 |
| Maggi, M | 1 |
| Orme, C | 1 |
| Imaeda, S | 1 |
| Mauras, N | 1 |
| Torres-Santiago, L | 1 |
| Taboada, M | 1 |
| Santen, R | 1 |
4 reviews available for oxybutynin and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
Pharmaceutical development and clinical effectiveness of a novel gel technology for transdermal drug delivery.
Topics: Administration, Cutaneous; Alprazolam; Animals; Anti-Anxiety Agents; Drug Delivery Systems; Estradio | 2005 |
Transdermal delivery of testosterone.
Topics: Administration, Cutaneous; Androgens; Gels; Humans; Hypogonadism; Male; Skin Absorption; Testosteron | 2015 |
Update in testosterone therapy for men.
Topics: Administration, Oral; Delayed-Action Preparations; Humans; Hypogonadism; Injections, Intramuscular; | 2011 |
Estrogen therapy in Turner syndrome: does the type, dose and mode of delivery matter?
Topics: Administration, Cutaneous; Administration, Oral; Child; Estradiol; Estrogen Replacement Therapy; Est | 2012 |
1 trial available for oxybutynin and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
Cardiovascular Safety of Testosterone-Replacement Therapy.
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Double-Blind Method; Ge | 2023 |
1 other study available for oxybutynin and Hypergonadotropic Hypogonadism
| Article | Year |
|---|---|
Images in clinical medicine. Eschar formation from testosterone patch.
Topics: Administration, Cutaneous; Aged; Humans; Hypogonadism; Male; Skin; Testosterone; Transdermal Patch | 2012 |